A multicenter, prospective observational study of pegfilgrastim for the management of febrile neutropenia during ramucirumab plus docetaxel for patients with advanced non-small cell lung cancer (CJLSG 1602)
Not Applicable
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000026927
- Lead Sponsor
- Central Japan Lung Study Group (CJLSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1) Active infection 2) Patients had brain tumors and/or brain metastases (symptomatic or requiring treatment) 3) Evidence of tumor invading a perihilar blood vessel 4) Having a cavitating lung tumor 5) History of pulmonary hemorrhage or hemoptysis over 2.5 ml within 2 months 6) Evidence of tumor invading segmental bronchus 7) Severe gastrointestinal complications 8) Having a history or evidence of thrombosis 9) Severe hypertension 10) Having a history or evidence of ILD complication 11) Having an allergy of ramucirumab, docetaxel and pegfilgrastim 12) Having a severe mental disorder 13) Pregnant woman 14) Patients whose participation in the trial is judged to be inappropriate by the doctor
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method